Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.95B 3.41B 3.2B 2.91B 5.48B 378B 5.57B 37.55B 14.68B 189B 14.82B 14.5B 628B P/E 2026 *
-45.4x
P/E 2027 * -140x
Enterprise Value 3.83B 3.31B 3.11B 2.83B 5.31B 366B 5.4B 36.41B 14.24B 183B 14.38B 14.06B 609B EV / Sales 2026 *
13.1x
EV / Sales 2027 * 10.6x
Free-Float
98.52%
Yield 2026 *
-
Yield 2027 * -
1 day+1.14%
1 week-0.76%
Current month+9.61%
1 month+8.03%
3 months+92.83%
6 months+54.24%
Current year+52.34%
1 week 24
Extreme 24
26.16
1 month 20.9
Extreme 20.9
26.16
Current year 12
Extreme 12
26.16
1 year 11.92
Extreme 11.92
26.16
3 years 2.28
Extreme 2.28
26.16
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Sell

Executive/Senior Manager

-3,000 0.0019%
30/07/26 Sell

Executive/Senior Manager

-1,299 0.0008%
21/07/26 Fiscal year

Founder

1,062,000 0.6636%
Change 5-day change 1-year change 3-year change Capi.($)
+1.14%-0.76%+89.72%+293.32% 3.95B
-3.17%-12.64%+36.50%+64.80% 3.32B
+7.06%+10.09%+173.73%-7.06% 3.16B
-4.35%-2.93%+282.77%+369.15% 2.34B
-3.10%+1.70%-21.24%-25.97% 2.31B
-0.43%+3.68%+9.37% - 1.3B
+0.78%+11.25%+15.23%+49.19% 1.04B
-1.38%-8.51%+118.39%-45.09% 849M
+29.91%+22.82%-6.81%+358.96% 616M
-0.20%+6.38%-34.43%+0.16% 566M
Average +2.63%+1.22%+66.32%+117.50% 1.95B
Weighted average by Cap. +0.84%-0.48%+89.60%+131.67%

Financials

2026 *2027 *
Net sales 293M 253M 238M 216M 407M 28.04B 414M 2.79B 1.09B 14.04B 1.1B 1.08B 46.66B 359M 310M 291M 265M 498M 34.28B 506M 3.41B 1.33B 17.17B 1.35B 1.32B 57.05B
Net income -85.78M -74.09M -69.62M -63.32M -119M -8.2B -121M -816M -319M -4.11B -322M -315M -13.65B -27.55M -23.8M -22.36M -20.34M -38.24M -2.63B -38.87M -262M -102M -1.32B -103M -101M -4.38B
Net Debt -119M -103M -96.8M -88.03M -166M -11.4B -168M -1.13B -443M -5.71B -448M -438M -18.98B -166M -143M -134M -122M -230M -15.83B -234M -1.57B -616M -7.93B -622M -608M -26.35B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
14/08/26 $24.74 +1.14% 1,743,593
13/08/26 $24.46 -3.13% 1,537,646
12/08/26 $25.25 -0.55% 1,706,891
11/08/26 $25.39 -0.24% 2,956,649
10/08/26 $25.45 +2.09% 2,366,094
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
24.74USD
Average target price
25.07USD
Spread / Average Target
+1.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock